STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer - European Medical Journal

STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now